Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Genelux Corporation
Seagen Inc.
Incyte Corporation
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
AstraZeneca
Daiichi Sankyo
Akeso
Genmab
Summit Therapeutics
Amgen
AbbVie
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pfizer
Hoffmann-La Roche
AstraZeneca
Hoffmann-La Roche
AstraZeneca
Hoffmann-La Roche
Hoffmann-La Roche
Akeso
Merck Sharp & Dohme LLC
ImmunityBio, Inc.
Bristol-Myers Squibb
Hoffmann-La Roche
Tempest Therapeutics
AbbVie
Pfizer
Qilu Pharmaceutical Co., Ltd.
Prestige Biopharma Limited
Hoffmann-La Roche
AGO Research GmbH
Celltrion
AstraZeneca
Shanghai Henlius Biotech
Samsung Bioepis Co., Ltd.
NaviFUS Corporation
Ascletis Pharma Inc
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Pfizer
Taiho Oncology, Inc.
Mabscale, LLC